We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+49.04%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$18.8B
AUM Growth
+$4.11B
Cap. Flow
-$554M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.02%
Holding
117
New
8
Increased
21
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$227M
2
DBVT
DBV Technologies
DBVT
+$72.8M
3
KOD icon
Kodiak Sciences
KOD
+$69.2M
4
KRRO icon
Korro Bio
KRRO
+$19.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$15.7M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$627M
2
AMRN
Amarin Corp
AMRN
+$134M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$72.9M
4
NGNE icon
Neurogene
NGNE
+$39.4M
5
CBAY
Cymabay Therapeutics
CBAY
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.59%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$22.5B
$58.4M 0.31%
2,445,265
+215,505
+10% +$4.38M
KRYS icon
27
Krystal Biotech
KRYS
$10.7B
$57.3M 0.3%
1,034,674
– –
BCEL
28
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$54.7M 0.29%
3,532,760
– –
BOLD
29
DELISTED
Audentes Therapeutics, Inc
BOLD
$48.2M 0.26%
804,720
-701,718
-47% -$26.3M
CERS icon
30
Cerus
CERS
$575M
$45.4M 0.24%
10,749,937
– –
NGNE icon
31
Neurogene
NGNE
$656M
$41.9M 0.22%
169,887
-395,397
-70% -$39.4M
GWPH
32
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$38.8M 0.21%
370,845
– –
BCRX icon
33
BioCryst Pharmaceuticals
BCRX
$2.44B
$37.8M 0.2%
10,946,166
-1,779,306
-14% -$4.48M
QURE icon
34
uniQure
QURE
$2.78B
$37.1M 0.2%
517,700
– –
AUPH icon
35
Aurinia Pharmaceuticals
AUPH
$1.94B
$34.5M 0.18%
+1,701,929
New +$15.7M
ADPT icon
36
Adaptive Biotechnologies
ADPT
$3.54B
$33.4M 0.18%
1,115,411
-50,000
-4% -$1.44M
ALLK
37
DELISTED
Allakos
ALLK
$32.4M 0.17%
339,690
– –
ASMB icon
38
Assembly Biosciences
ASMB
$494M
$31.5M 0.17%
128,468
+61,531
+92% +$11.3M
KNSA icon
39
Kiniksa Pharmaceuticals
KNSA
$6.19B
$31M 0.16%
2,799,577
– –
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
$29.2M 0.16%
739,016
+531,987
+257% +$9.34M
MRUS
41
DELISTED
Merus
MRUS
$28.7M 0.15%
2,037,469
+877,455
+76% +$14.1M
URGN icon
42
UroGen Pharma
URGN
$1.98B
$27.7M 0.15%
831,488
+83,737
+11% +$2.29M
AIMT
43
DELISTED
Aimmune Therapeutics
AIMT
$22.6M 0.12%
673,908
– –
KRRO icon
44
Korro Bio
KRRO
$147M
$21.6M 0.11%
+24,629
New +$19.2M
ALKS icon
45
Alkermes
ALKS
$8.15B
$16.2M 0.09%
793,130
+168,100
+27% +$3.34M
UROV
46
DELISTED
Urovant Sciences Ltd.
UROV
$15.5M 0.08%
+1,000,000
New +$10.8M
APLS
47
DELISTED
Apellis Pharmaceuticals
APLS
$15.2M 0.08%
496,969
+183,244
+58% +$5.07M
XNCR icon
48
Xencor
XNCR
$1.47B
$14.7M 0.08%
428,120
– –
SYRE icon
49
Spyre Therapeutics
SYRE
$8.44B
$13.1M 0.07%
68,544
– –
HOOK
50
DELISTED
HOOKIPA Pharma
HOOK
$10.9M 0.06%
89,286
– –
1
2
3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, Baker Bros. Advisors held 117 positions worth $18.8B, up 28% from $14.7B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q4 2019 filing shows 8 new, 21 increased, 10 reduced and 18 closed positions. Its largest new stake was Exact Sciences: 2,585,791 shares worth $239M. The largest sale was Genomic Health, Inc., an estimated $627M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Financials and Technology.

  • Baker Bros. Advisors's largest Q4 2019 buy was Exact Sciences: 2,585,791 shares worth $239M.
  • Baker Bros. Advisors added most to DBV Technologies in Q4 2019, an estimated $72.8M increase.
  • Baker Bros. Advisors's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $134M.
  • Baker Bros. Advisors fully exited Genomic Health, Inc. in Q4 2019, selling an estimated $627M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $18.8B portfolio in Q4 2019.
  • Baker Bros. Advisors opened 8 new positions and closed 18 in Q4 2019.
  • Baker Bros. Advisors's portfolio value rose 28% quarter-over-quarter to $18.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.